Submitting Advances and Learnings in Personalised Medicine (APM)

APM are any activity carried out by projects, initiatives, infrastructures, research and healthcare centres, which are successfully contributing to the developments of PM. These activities can exemplify achievements and learnings in research, innovation or implementation in healthcare systems or the overarching cooperation by them.

An APM should show the potential that PM approaches have already today and give an idea about their impact in future. APM can be related to projects/initiatives, infrastructures and centres dealing with PM at a regional, national and international level.

Selection criteria for APM

It is important that an APM fulfills these five overall criteria:

1. It is linked to PM and this link is elaborated and made very clear in the example text.
2. The benefit for patients and society, short or long term, is described in clear terms.
3. It is written in a language, which can be understood by a broad audience and not only by experts in the field.
4. The text contains required components that can be used to disseminate the APM through the EP PerMed web.
5. It is in the public domain.

Other criteria that will be considered during the evaluation, and that overall contribute to the relevance of the candidate APM, are:

1. It has contributed to knowledge production documented by:
   1. Recent peer reviewed publications and citations
   2. Recent presentations at national and international conferences
   3. Awards in the context of PM
   4. Policy documents and publications including business- and incentives-models
2. It has contributed to techniques/research tools/infrastructures:
   1. Development / application of novel research techniques
   2. Establishment of new sample collections/cohorts/ research data sets/databases
   3. Publication and/or development of relevant patents
3. It has contributed to the enhancement of collaboration/ human capacity building:
   1. Education and training of scientists, researchers, health professionals, etc.
   2. New national/international collaboration or strategic partnership including public-private partnerships (including research teams, industrial partners, health agencies and public-private partnerships)
   3. The example has the potential to be implemented in other regions/countries (transferability)
4. It has contributed to learnings and developments of policies, practices, guidelines, standards:
   1. Dissemination and knowledge-transfer events or networks established with research, policy-makers and health professionals
   2. Policy briefing papers, practical handbooks and other material disseminated
   3. Contribution of research to clinical treatment or best practice guidelines
   4. Development of new clinical practices enabling PM-based approaches
   5. Contribution to development of new regulatory procedures and processes allowing access of PM based treatments for patients
   6. Development of national and international procedures and guidelines allowing access to data for use in PM across borders
5. It has contributed to advancements and learnings for health prevention, public health, or health sector benefits:
   1. Contribution of respective research and innovation to health dissemination initiatives
   2. Contribution of respective research and innovation to health service efficiency, improved primary care or introduction of preventative health measures
6. It has contributed to health economic benefits and learnings:
   1. Supporting activities to develop marketable products
   2. Economic gains and learnings from improved patient care and population health where link to the respective research/study can be established.

Early or basic research projects/starting initiatives can be selected for APM, if they can highlight the potential and future opportunities for PM.

If selected, the APM gets visibility by being published on EP PerMed website and social media and is included in the EP PerMed newsletter.

Label of “Best Practice” (BP) and Best Practice Awards

APM positively evaluated by EP PerMed can be labeled as Best Practice, if deemed appropriate.

BP can be defined as any APM which has demonstrated excellent contribution to create value for PM through research, innovation and/or implementation in healthcare systems or overarching cooperation including relevant aspects of the value continuum in the field of PM.

The upgrade from APM to BP depends on:

1. Overall quality of the APM
2. Potential impact for PM
3. Sustainability
4. Transferability (potential for broader implementation)
5. Open field for comments highlighting the key successes and learnings as well as strengths and weaknesses of the APM/BP

Awards for BP could include (different exclusive options), but are not limited to:

• Invite to present to EP PerMed/ICPerMed conferences and events
• Invitation as experts to EP PerMed round tables and panel discussions
• Invitation to join in situ visits
• The possibility to be invited to take part in a network of PM clinics
• Being recognised as validation centres
• Part of or highlighted in a podcast
• Other, after discussion and approval by the EP PerMed

EP PerMed recognises that, considering the different nature of BP and their awardees (researchers, research centres, patient associations, healthcare systems, innovators, companies, policy makers, etc…) awards cannot be predefined. Thus, for each BP awarded, awards that are likely to match the needs of the awardee will be proposed and agreed upon.

Your application will be reviewed by EP PerMed and the outcome will be notified in due time.

If you need help or wish to reach out for any communication, please write to eppermed@dlr.de

Thank you for your application!